P/E ratio for ACADIA Pharmaceuticals (ACAD)
P/E ratio as of May 2024 (TTM): -16.5
According to ACADIA Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -16.5326. At the end of 2022 the company had a P/E ratio of -11.9.
P/E ratio history for ACADIA Pharmaceuticals from 2004 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -11.9 | -46.55% |
| 2021 | -22.2 | -25.16% |
| 2020 | -29.7 | 11.08% |
| 2019 | -26.7 | 222.44% |
| 2018 | -8.29 | -35.28% |
| 2017 | -12.8 | 3.96% |
| 2016 | -12.3 | -43.65% |
| 2015 | -21.9 | -35.25% |
| 2014 | -33.8 | -40.53% |
| 2013 | -56.8 | 351.92% |
| 2012 | -12.6 | 412.01% |
| 2011 | -2.45 | -181.82% |
| 2010 | 3.00 | -370.45% |
| 2009 | -1.11 | 111.99% |
| 2008 | -0.5233 | -92.44% |
| 2007 | -6.92 | 26.73% |
| 2006 | -5.46 | -14.64% |
| 2005 | -6.40 | 70.38% |
| 2004 | -3.75 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.6 | -164.35% | 🇺🇸 USA |
 Pfizer PFE | 15.2 | -191.64% | 🇺🇸 USA |
 Eli Lilly LLY | 142 | -959.57% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 11.3 | -168.17% | 🇺🇸 USA |
 Vanda Pharmaceuticals VNDA | 18.6 | -212.24% | 🇺🇸 USA |
 Adamas Pharmaceuticals
ADMS | N/A | N/A | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.